Recursion Pharmaceuticals, Inc. (RXRX) Tops Q1 EPS by 4c, offers outlook

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q1 EPS of ($0.22), $0.04 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $6.47 million versus the consensus estimate of $16.28 million.

Reiterate 2026 guidance of <$390 million operational cash burn, supporting runway into early 2028 without additional financing

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
• XORTX to voluntarily delist from TSX Venture Exchange